Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Industry Watch.
Press releases published on April 21, 2025
Inspire Medical Systems, Inc. Announces the Addition of Paul T. Hoff, M.D., M.S. and Ruchir P. Patel, M.D., F.A.C.P. as Vice President, Senior Medical Directors
GlobeNewswire
·
April 21, 2025
MINNEAPOLIS, April 21, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive …
Nexalin Technology Expresses Strong Support for Health Tech Investment Act to Advance Medicare Reimbursement for AI-Enabled Devices
GlobeNewswire
·
April 21, 2025
HOUSTON, TX, April 21, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced its support for the Health Tech …
Reflect Scientific Inc. Announces Strategic Market Transition and Substantial Cost Savings
GlobeNewswire
·
April 21, 2025
OREM, Utah, April 21, 2025 (GLOBE NEWSWIRE) -- Reflect Scientific Inc. (symbol: RSCF), a leading innovator in advanced refrigeration and cooling technologies, today announced significant financial improvements resulting from strategic market transitions …
Anavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer’s Disease and Related Disorders in the Middle East
GlobeNewswire
·
April 21, 2025
NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, …
Zevra Files Definitive Proxy Statement and Mails Letter to Stockholders
GlobeNewswire
·
April 21, 2025
Highlights 54.8% Total Stockholder Return Under Refreshed Board and Management Team Zevra Continues Growth Trajectory into a Global Commercial Rare Disease Company with Consistent Execution, New Product Launches, and Significant Financial Flexibility to …
Kraig Biocraft Laboratories Provides Production Update on Recombinant Spider Silk Operations
GlobeNewswire
·
April 21, 2025
ANN ARBOR, Mich., April 21, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company" or "Kraig Labs"), a world leader in spider silk technology*, is pleased to provide an update on recombinant spider silk production. The …
Invivyd Announces $30M Non-dilutive Loan Facility with Silicon Valley Bank
GlobeNewswire
·
April 21, 2025
WALTHAM, Mass., April 21, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that it has signed a $30 million term loan facility with …
Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at 2025 American Association for Cancer Research® (AACR) Annual Meeting
GlobeNewswire
·
April 21, 2025
NEW HAVEN, Conn., April 21, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today announced that new preclinical combination data …
BioCryst to Report First Quarter 2025 Financial Results on May 5
GlobeNewswire
·
April 21, 2025
RESEARCH TRIANGLE PARK, N.C., April 21, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2025 financial results on Monday, May 5, 2025. BioCryst management will host a …
Ascentage Pharma Announces Inclusion of Lisaftoclax and Olverembatinib in Chinese Society of Clinical Oncology (CSCO) 2025 Guidelines
GlobeNewswire
·
April 21, 2025
ROCKVILLE, Md. and SUZHOU, China, April 21, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs …
AccuStem Sciences, Inc. Announces Chairman Purchase of Shares
GlobeNewswire
·
April 21, 2025
LONDON and PHOENIX, Ariz., April 21, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced that its Chairman of the Board, Mr. Gabriele …
Amicus Therapeutics to Announce First Quarter 2025 Financial Results on May 1, 2025
GlobeNewswire
·
April 21, 2025
PRINCETON, N.J., April 21, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, May 1, 2025, at 8:30 a.m. ET to discuss financial results for the first …
Apellis Announces Craig Wheeler to Join the Board of Directors
GlobeNewswire
·
April 21, 2025
WALTHAM, Mass., April 21, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that Craig Wheeler, founder and chief executive officer of Headwaters Biotech Advisors, will join the Apellis Board of Directors, effective …
Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren’s Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402
GlobeNewswire
·
April 21, 2025
Eric Venker, M.D. (currently President and COO of Roivant) appointed as CEO of Immunovant and Tiago Girao appointed as CFO of Immunovant Pete Salzmann, M.D. retired from his role as Immunovant CEO and Director Leadership change is part of a broader …
Alumis and ACELYRIN Announce Amended Merger Agreement
GlobeNewswire
·
April 21, 2025
ACELYRIN stockholders to receive increased ownership in the combined company through revised exchange ratio; Alumis and ACELYRIN stockholders to now own approximately 52% and 48%, respectively, of the combined company on a fully diluted basis Merger …
Alumis and ACELYRIN Announce Amended Merger Agreement
GlobeNewswire
·
April 21, 2025
ACELYRIN stockholders to receive increased ownership in the combined company through revised exchange ratio; Alumis and ACELYRIN stockholders to now own approximately 52% and 48%, respectively, of the combined company on a fully diluted basis Merger …
Aclarion Announces Publication of Seminal Nociscan Cost-Effectiveness Analysis
GlobeNewswire
·
April 21, 2025
Independent Cost-Effectiveness Analysis Concludes Nociscan is Effective and Less Costly Compared to Provocative Discography Conclusions Illustrate Nociscan Saves $1,712 per Patient and Improves Surgical Success by 10% BROOMFIELD, Colo., April 21, 2025 ( …